Press Release

Exothera’s CTO Patrick Thiaville nominated as a member of Alliance for mRNA Medicines Board

November 28, 2023

WASHINTON, D.C., and BRUSSELS, Belgium, 28 November 2023 – Patrick Thiaville, Nucleic Acids Chief Technology Officer at Exothera, a Univercells company and full-service Contract Development and Manufacturing Organization (CDMO) delivering customized process development and cGMP manufacturing services for vaccines, viral vectors, and nucleic acids, has been nominated as a member of the Alliance for mRNA Medicines (AMM) board.

AMM is the first and only scientific and policy organization singularly focused on advancing and advocating for global mRNA innovation and the sector’s top policy priorities before legislative and regulatory bodies in North America, Europe, and Asia. The Alliance issued its announcement at the 11th International mRNA Health Conference in Berlin, Germany.

Alliance members represent some of the most recognized mRNA innovators in the field. Bringing the best minds together, AMM aims to overcome the most critical obstacles inhibiting the advancement of mRNA research, development, and manufacturing.

Patrick’s technical knowledge and leadership in GMP operations, Process Development, and MSAT activities come from over 20 years of expertise in designing and modifying microorganisms and plasmids.  He has successfully led teams in clinical manufacturing of live biotherapeutic products and the design and build-out of manufacturing infrastructure. Patrick was a thought leader for cGMP plasmid manufacturing at Thermo Fisher Scientific and has been featured in several industry magazines, including Outsourced Pharma, the Medicine Maker and Cell& Since May 2023, Patrick has been the nucleic acids division CTO at Exothera.

Last April, Exothera announced a partnership with Quantoom Biosciences to gain access to Quantoom’s Ntensify™ technology, a continuous-batch production platform for RNA. The partnership allowed Exothera to be the first CDMO in the world to offer this off-the-shelf process for the continuous-batch production of RNA as a service. Continuous-batch manufacturing of RNA can provide significant advantages in terms of efficiency, productivity, quality control, cost-effectiveness, and scalability.

Patrick Thiaville commented: “It is an honor to be part of this initiative. mRNA science is revolutionizing drug and vaccine development, and I believe AMM will bring together scientists, policymakers, companies, and governments to bring this revolution closer to patients. I am sure Exothera, with this RNA continuous manufacturing service, will contribute heavily to the success of AMM and mRNA therapeutics.”

About Exothera

Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies developed within the Univercells group. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of vaccines, viral vectors, and nucleic acids. At Exothera and Univercells, our mission is to make life-changing therapies available to all. For more information, visit

For more information please contact:

Michele Marini – MarCom Associate | +32 472 136 077

Exothera Nucleic Acids Strengthens Team with Industry Expert Patrick Thiaville